Stage IV Melanoma Completed Phase 1 / 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0028660 (Stage IV Melanoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00074308Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced CancersTreatment